Search
Sutro Biopharma Inc
STROAdd to Watchlist
24.170USD
-0.650-2.62%
Close 07-31 16:00（ET）Quotes delayed by 15 min
400.51MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Sutro Biopharma Inc is 8.15, ranking 166 out of 385 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 100.00 and a low of 8.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
47.750
Target Price
+97.56%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Sutro Biopharma Inc
STRO
13
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Sutro Biopharma Inc's expected revenue for the next quarter?
Sutro Biopharma Inc's expected revenue is 12.95M.
What is Sutro Biopharma Inc's price target?
Analysts forecast that Sutro Biopharma Inc's price target is USD 30.00, with the highest forecast at USD 100.00 and the lowest forecast at USD 8.00.
How have Sutro Biopharma IncSTRO's recent earnings per share performed?
The market expectation was USD -2.94, while Sutro Biopharma IncSTRO's earnings per share (EPS) for the previous quarter was USD -5.35. EPS for the next quarter is expected at USD -2.22.
What is the analyst rating for Sutro Biopharma Inc?
Based on the ratings of Sutro Biopharma Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.